UY34860A - Sistema de expresión en cho. - Google Patents

Sistema de expresión en cho.

Info

Publication number
UY34860A
UY34860A UY0001034860A UY34860A UY34860A UY 34860 A UY34860 A UY 34860A UY 0001034860 A UY0001034860 A UY 0001034860A UY 34860 A UY34860 A UY 34860A UY 34860 A UY34860 A UY 34860A
Authority
UY
Uruguay
Prior art keywords
cho
expression system
sequence
cell line
encoding
Prior art date
Application number
UY0001034860A
Other languages
English (en)
Spanish (es)
Inventor
Bruno Dumas
Catherine Devaud
Nabil Lounis
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of UY34860A publication Critical patent/UY34860A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93Ligases (6)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y603/00Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/01Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
    • C12Y603/01002Glutamate-ammonia ligase (6.3.1.2)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/22Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00Vectors comprising a special origin of replication system
    • C12N2820/55Vectors comprising a special origin of replication system from bacteria
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/60Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY0001034860A 2012-06-14 2013-06-14 Sistema de expresión en cho. UY34860A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12305677.2A EP2674495A1 (en) 2012-06-14 2012-06-14 CHO expression system

Publications (1)

Publication Number Publication Date
UY34860A true UY34860A (es) 2014-01-31

Family

ID=48700539

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034860A UY34860A (es) 2012-06-14 2013-06-14 Sistema de expresión en cho.

Country Status (15)

Country Link
US (1) US9334489B2 (enExample)
EP (2) EP2674495A1 (enExample)
CN (2) CN104540950A (enExample)
AR (1) AR091418A1 (enExample)
AU (1) AU2013276467B2 (enExample)
CA (1) CA2876550C (enExample)
DK (1) DK2861741T3 (enExample)
ES (1) ES2627954T3 (enExample)
HU (1) HUE032968T2 (enExample)
IN (1) IN2014KN02823A (enExample)
MX (1) MX353499B (enExample)
SG (1) SG11201408051VA (enExample)
TW (1) TWI605123B (enExample)
UY (1) UY34860A (enExample)
WO (1) WO2013186371A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR102333A1 (es) 2014-08-19 2017-02-22 Regeneron Pharma Selectividad eficiente de proteínas recombinadas
SG11201702516UA (en) * 2014-10-23 2017-04-27 Sanofi Sa Novel selection marker for cell transfection and protein production
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
ES2823173T3 (es) 2016-01-27 2021-05-06 Just Biotherapeutics Inc Promotor híbrido y usos del mismo
WO2018047154A1 (en) 2016-09-07 2018-03-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anti-nkp46 antibodies and therapeutic use of same
CN111093641A (zh) 2017-05-24 2020-05-01 托埃瑞斯有限责任公司 谷氨酰胺合成酶用于治疗高氨血症的用途
IL253984A0 (en) 2017-08-14 2017-09-28 Yeda Res & Dev Immunotherapy against aranviruses that bind through transferrin receptor 1 (tfr1
CN108085337B (zh) * 2017-12-28 2020-10-16 未名生物医药有限公司 一种gs表达系统细胞株的筛选方法
CN109988777A (zh) * 2017-12-29 2019-07-09 南京金斯瑞生物科技有限公司 谷氨酰胺合成酶基因以及应用
US20220356487A1 (en) * 2019-06-07 2022-11-10 Biocon Biologics India Limited Mammalian expression vectors
IL276627A (en) 2020-08-10 2022-03-01 Yeda Res & Dev Compositions for diagnosis and treatment of coronavirus infections
IL301442A (en) 2020-09-21 2023-05-01 Sanofi Sa Production of a recombinant Chinese hamster ovary cell line (CHO) for the production of a high-yield therapeutic protein
EP4384623A4 (en) * 2021-08-03 2025-09-24 Shanghai Zhenge Biotechnology Co Ltd SELECTABLE MARKERS FOR EUKARYOTIC EXPRESSION SYSTEM
CN118804978A (zh) * 2021-12-27 2024-10-18 上海臻格生物技术有限公司 用于重组生产系统的新型标志物
CN115287300A (zh) * 2022-08-11 2022-11-04 无锡多宁生物科技有限公司 一种增强ExpiCHO细胞瞬时转染抗体表达的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8924021D0 (en) * 1989-10-25 1989-12-13 Celltech Ltd Recombinant dna method and vectors for the use therein
KR100267720B1 (ko) * 1997-12-29 2001-03-02 박호군 사람 글루타민 합성효소 유전자를 포함하는 발현벡터 및 이를 이용하여 동물세포에서 에리트로포이에틴을 고수율로 생산하는 방법
GB0216648D0 (en) * 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
JP4764818B2 (ja) * 2003-04-11 2011-09-07 メディミューン,エルエルシー 組換えil−9抗体およびその使用
US7244616B2 (en) * 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
EP2298890A1 (en) * 2004-12-30 2011-03-23 Agency for Science, Technology and Research Chinese hamster apoptosis-related genes
GB0508154D0 (en) * 2005-04-22 2005-06-01 Lonza Biologics Plc Mammalian expression vector comprising the mCMV promoter and first intron of hCMV major immediate early gene
GB0510277D0 (en) * 2005-05-20 2005-06-29 Lonza Biologics Plc High-level expression of recombinant antibody in a mammalian host cell
EP2109674A2 (en) * 2007-01-08 2009-10-21 Millipore Corporation High expression cell line that eliminates gene amplification
LT2592148T (lt) * 2007-10-12 2018-12-10 F. Hoffmann-La Roche Ag Baltymų ekspresavimas iš kelių nukleorūgščių
MY158903A (en) 2007-11-16 2016-11-30 Univ Rockefeller Antibodies specific for the protofibril form of beta-amyloid protein

Also Published As

Publication number Publication date
SG11201408051VA (en) 2015-01-29
TWI605123B (zh) 2017-11-11
TW201402817A (zh) 2014-01-16
WO2013186371A1 (en) 2013-12-19
CA2876550C (en) 2021-07-13
MX2014015280A (es) 2015-06-23
DK2861741T3 (en) 2017-07-17
AU2013276467A1 (en) 2015-01-15
US9334489B2 (en) 2016-05-10
CA2876550A1 (en) 2013-12-19
EP2674495A1 (en) 2013-12-18
MX353499B (es) 2018-01-16
EP2861741A1 (en) 2015-04-22
AR091418A1 (es) 2015-02-04
HUE032968T2 (en) 2017-11-28
US20150140607A1 (en) 2015-05-21
CN104540950A (zh) 2015-04-22
EP2861741B1 (en) 2017-04-12
AU2013276467B2 (en) 2018-08-30
IN2014KN02823A (enExample) 2015-05-08
CN107881151A (zh) 2018-04-06
ES2627954T3 (es) 2017-08-01

Similar Documents

Publication Publication Date Title
UY34860A (es) Sistema de expresión en cho.
UY40555A (es) Métodos y composiciones para la expresión génica en plantas
DK2831241T3 (da) Kunstige nukleinsyremolekyler til forbedret protein- eller peptidekspression.
MX350050B (es) Proteinas toxicas para especies de insectos hemipteros.
MX2021010668A (es) Proteinas de fusion de citoquinas.
UY32501A (es) Anticuerpo antagonista específico para el heterodímero alfa4-beta7
CR20120371A (es) Antagonistas de pcsk9
MX384628B (es) Polipéptidos que tienen actividad de transgalactosilación.
PE20151775A1 (es) Polipeptidos de fenilalanina amoniaco liasa modificados por ingenieria genetica
UY34227A (es) Acido nucleico recombinante que codifica el gen de la toxina axmi270, vectores, células, plantas y sus métodos de empleo
MX2014005108A (es) Constructos de polipeptidos y sus usos.
UY34254A (es) Proteínas y péptidos modificados.
EA201491388A1 (ru) Рекомбинантные белки фактора viii
MX359315B (es) Vacuna de adn para usarse en pacientes con cancer pancreatico.
EA201692025A1 (ru) Доставка белков, осуществляемая на основе бактерий
MX387400B (es) Células de mamífero que expresan antígenos de citomegalovirus.
MX2015000754A (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
JOP20140087B1 (ar) بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
MX383206B (es) Preparación de anticuerpos de cultivos de célula de ovario de hámster chino para conjugación.
DK3464338T3 (da) Modificeret rna, der koder for vegf-a-polypeptider, formuleringer og anvendelser forbundet dermed
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
EA201270263A1 (ru) Стрессоустойчивые растения
BR112015004629A2 (pt) polipeptídeos de clostridium difficile como vacinas
MX2016006586A (es) Identificacion de una citocina de linfocitos b novedosa.
PL403939A1 (pl) Aptamery DNA rozpoznające metkę histydynową oraz ich zastosowanie

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20230130